Cynthia Sile, MD
Hematology & Oncology · Suffolk, VANPI 1568428043
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $150 of the $188 with a category attached, or 79.7%. Array Biopharma Inc accounts for 79.7% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $150, more than ten times the $12 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in VA, where the typical reported total is $1,232.
Across 3 payments — averaging $62.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Array Biopharma Inc$150
- Seagen Inc.$26
- Gilead$12
What the payments were for
- Speaking & faculty fees$15080%
- Education$3820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Array Biopharma Inc | 1 | $150 |
| Seagen Inc. | 1 | $26 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$188 in reported general payments places this provider in the 15th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 26 | $582,303 |
| RevlimidLenalidomide | 33 | $519,620 |
| Lenalidomide | 26 | $353,076 |
| ImbruvicaIbrutinib | 11 | $130,079 |
| EliquisApixaban | 52 | $38,390 |
| Imatinib Mesylate | 26 | $21,192 |
| XareltoRivaroxaban | 16 | $13,386 |
| Exemestane | 35 | $3,059 |
| Dexamethasone | 77 | $2,438 |
| Letrozole | 96 | $1,606 |
| Ondansetron OdtOndansetron | 83 | $1,472 |
| Hydroxyurea | 58 | $1,270 |
| Tamoxifen Citrate | 62 | $1,199 |
| Anastrozole | 18 | $373 |
| Acyclovir | 44 | $334 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Suffolk
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.